Syneos Health Zukünftiges Wachstum

Future Kriterienprüfungen 3/6

Syneos Health wird ein jährliches Gewinn- und Umsatzwachstum von 33.7% bzw. 1.4% prognostiziert. Der Gewinn pro Aktie wird voraussichtlich wachsen um 40.1% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich 9.7% betragen.

Wichtige Informationen

33.7%

Wachstumsrate der Gewinne

40.1%

EPS-Wachstumsrate

Life Sciences Gewinnwachstum	16.2%
Wachstumsrate der Einnahmen	1.4%
Zukünftige Eigenkapitalrendite	9.7%
Analystenabdeckung	Good
Zuletzt aktualisiert	28 Sep 2023

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Is There An Opportunity With Syneos Health, Inc.'s (NASDAQ:SYNH) 49% Undervaluation?

Jun 18

Is Now The Time To Look At Buying Syneos Health, Inc. (NASDAQ:SYNH)?

Jun 03

We Think Syneos Health (NASDAQ:SYNH) Can Stay On Top Of Its Debt

May 19

Do Syneos Health's (NASDAQ:SYNH) Earnings Warrant Your Attention?

Apr 08

Syneos Health: Upside Opportunity After Unexpected Correction In CRO Market, M&A Rumors

Mar 27

Is Now An Opportune Moment To Examine Syneos Health, Inc. (NASDAQ:SYNH)?

Mar 05

Is Syneos Health (NASDAQ:SYNH) A Risky Investment?

Feb 18

Are Investors Undervaluing Syneos Health, Inc. (NASDAQ:SYNH) By 39%?

Feb 03

With EPS Growth And More, Syneos Health (NASDAQ:SYNH) Is Interesting

Jan 04

Syneos Health's Double-Digit Revenue Growth Sets The Tone For A Strong 2022

Dec 03

Is It Too Late To Consider Buying Syneos Health, Inc. (NASDAQ:SYNH)?

Dec 03

Gewinn- und Umsatzwachstumsprognosen

NasdaqGS:SYNH - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2025	5,478	267	467	463	7
12/31/2024	5,250	220	463	451	7
12/31/2023	5,146	43	336	438	8
6/30/2023	5,419	71	162	253	N/A
3/31/2023	5,414	148	289	387	N/A
12/31/2022	5,393	266	334	427	N/A
9/30/2022	5,407	287	392	489	N/A
6/30/2022	5,419	278	323	405	N/A
3/31/2022	5,340	242	325	394	N/A
12/31/2021	5,213	235	393	450	N/A
9/30/2021	4,980	251	337	379	N/A
6/30/2021	4,730	236	444	486	N/A
3/31/2021	4,461	198	542	591	N/A
12/31/2020	4,416	193	375	425	N/A
9/30/2020	4,489	192	420	472	N/A
6/30/2020	4,567	187	324	390	N/A
3/31/2020	4,720	195	229	293	N/A
12/31/2019	4,676	131	255	318	N/A
9/30/2019	4,608	86	208	270	N/A
6/30/2019	4,546	17	272	322	N/A
3/31/2019	4,452	19	292	337	N/A
12/31/2018	4,390	24	249	303	N/A
9/30/2018	3,995	-36	221	280	N/A
6/30/2018	3,472	-174	104	165	N/A
3/31/2018	2,658	-184	21	76	N/A
12/31/2017	1,853	-138	154	198	N/A
9/30/2017	1,365	-86	81	124	N/A
6/30/2017	1,033	89	128	163	N/A
3/31/2017	1,033	116	N/A	186	N/A
12/31/2016	1,030	113	N/A	109	N/A
9/30/2016	1,009	106	N/A	159	N/A
6/30/2016	984	116	N/A	154	N/A
3/31/2016	952	109	N/A	160	N/A
12/31/2015	915	117	N/A	205	N/A
9/30/2015	887	33	N/A	155	N/A
6/30/2015	860	8	N/A	146	N/A
3/31/2015	837	0	N/A	144	N/A
12/31/2014	810	-27	N/A	131	N/A
9/30/2014	770	13	N/A	142	N/A
6/30/2014	732	-1	N/A	121	N/A
3/31/2014	687	-27	N/A	86	N/A
12/31/2013	652	-42	N/A	37	N/A
12/31/2012	579	-60	N/A	43	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: SYNHDas prognostizierte Gewinnwachstum (33.7% pro Jahr) liegt über der Sparquote (2.2%).

Ertrag vs. Markt: SYNHDie Erträge des Unternehmens (33.7% pro Jahr) werden voraussichtlich schneller wachsen als der Markt US (14.7% pro Jahr).

Hohe Wachstumserträge: SYNHEs wird erwartet, dass die Erträge des Unternehmens in den nächsten 3 Jahren erheblich steigen werden.

Einnahmen vs. Markt: SYNHDie Einnahmen des Unternehmens (1.4% pro Jahr) werden voraussichtlich langsamer wachsen als der Markt US (8.4% pro Jahr).

Hohe Wachstumseinnahmen: SYNHDie Einnahmen des Unternehmens (1.4% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: SYNHDie Eigenkapitalrendite des Unternehmens wird in 3 Jahren voraussichtlich niedrig sein (9.7 %).

Syneos Health Zukünftiges Wachstum

Future Kriterienprüfungen 3/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Consensus EPS estimates fall by 70%

Consensus EPS estimates fall from profit to US$0.31 loss, revenue upgraded

Syneos Health, Inc. Provides Earnings Guidance for the Fiscal Year 2023

Consensus EPS estimates fall by 11%

Price target decreased by 10% to US$36.95

Syneos Health, Inc. Reaffirms Revenue Guidance for the Full Year 2022

Recent updates

Syneos Health Files Form 15

Syneos Health, Inc. Announces Chief Executive Officer Changes

Syneos Health, Inc. Announces Management Changes

Patient Square Capital, LP, Elliott Investment Management L.P. and Veritas Capital Fund Management, L.L.C completed the acquisition of Syneos Health, Inc. (NasdaqGS:SYNH) from a group of shareholders.

Syneos Health Names Terttu Haring President, Clinical Sites & Patients

Levi & Korsinsky Notifies Syneos Health, Inc. Investors of A Class Action Lawsuit and Upcoming Deadline

Consensus EPS estimates fall by 70%

The Klein Law Firm Announces That a Class Action Complaint Has Been Filed on Behalf of Shareholders of Syneos Health, Inc

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Syneos Health, Inc. to Report Q2, 2023 Results on Aug 09, 2023

Robbins Geller Rudman & Dowd LLP Files Class Action Lawsuit Against Syneos Health, Inc

Syneos Health Appoints Hillary Bochniak as Chief Human Resources Officer

Syneos Health, Inc. Appoints Batisha Anson to Global Head, Patient Diversity and Health Equity

Consensus EPS estimates fall from profit to US$0.31 loss, revenue upgraded

Patient Square Capital, LP, Elliott Investment Management L.P. and Veritas Capital Fund Management, L.L.C entered into an agreement to acquire Syneos Health, Inc. (NasdaqGS:SYNH) in a transaction valued at approximately $7.5 billion.

First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Investor sentiment improves as stock rises 17%

Is Now The Time To Look At Buying Syneos Health, Inc. (NASDAQ:SYNH)?

Does Syneos Health (NASDAQ:SYNH) Have A Healthy Balance Sheet?

Is Syneos Health, Inc. (NASDAQ:SYNH) Trading At A 40% Discount?

Full year 2022 earnings: EPS in line with analyst expectations despite revenue beat

Syneos Health, Inc. Provides Earnings Guidance for the Fiscal Year 2023

Consensus EPS estimates fall by 11%

Price target decreased by 10% to US$36.95

Syneos Health, Inc. to Report Q4, 2022 Results on Feb 16, 2023

Syneos Health, Inc. Reaffirms Revenue Guidance for the Full Year 2022

Should You Investigate Syneos Health, Inc. (NASDAQ:SYNH) At US$34.33?

Is Syneos Health (NASDAQ:SYNH) Using Too Much Debt?

High number of new directors

Investor sentiment deteriorated over the past week

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Syneos Health, Inc. Revises Earnings Guidance for the Fiscal Year 2022

Here's Why Syneos Health (NASDAQ:SYNH) Has Caught The Eye Of Investors

Syneos Health Adds Hub Patient Suite to Deployment Solutions Business

Syneos Health, Inc. to Report Q3, 2022 Results on Nov 04, 2022

Syneos Health, Inc. Announces Executive Changes

Price target decreased to US$69.73

Syneos, Datavant expand partnership on data analytics for clinical trials

Investor sentiment deteriorated over the past week

Syneos Health falls 13% after update on outlook

When Should You Buy Syneos Health, Inc. (NASDAQ:SYNH)?

Is Syneos Health (NASDAQ:SYNH) A Risky Investment?

Syneos Health, Inc. (NasdaqGS:SYNH) acquired Boco Digital Media, LLC.

Second quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Syneos Health, Inc. Provides Earnings Guidance for the Third Quarter of 2022

Syneos Health Q2 2022 Earnings Preview

With EPS Growth And More, Syneos Health (NASDAQ:SYNH) Makes An Interesting Case

Syneos Health, Inc. to Report Q2, 2022 Results on Aug 02, 2022

Syneos: Upside Could Be Priced In, Valuations Unsupportive

Is There An Opportunity With Syneos Health, Inc.'s (NASDAQ:SYNH) 49% Undervaluation?

Is Now The Time To Look At Buying Syneos Health, Inc. (NASDAQ:SYNH)?

We Think Syneos Health (NASDAQ:SYNH) Can Stay On Top Of Its Debt

Consensus forecasts updated

High number of new directors

Syneos Health, Inc. Revises Earnings Guidance for the Fiscal Year 2022

First quarter 2022 earnings: EPS misses analyst expectations

Syneos Health Announces Executive Promotions

Syneos Health, Inc., Annual General Meeting, May 25, 2022

Syneos Health, Inc. to Report Q1, 2022 Results on Apr 29, 2022

Do Syneos Health's (NASDAQ:SYNH) Earnings Warrant Your Attention?

Syneos Health: Upside Opportunity After Unexpected Correction In CRO Market, M&A Rumors

Is Now An Opportune Moment To Examine Syneos Health, Inc. (NASDAQ:SYNH)?

Consensus forecasts updated

Consensus forecasts updated

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Syneos Health, Inc. Provides Earnings Guidance for the First Quarter of 2022

Is Syneos Health (NASDAQ:SYNH) A Risky Investment?

Are Investors Undervaluing Syneos Health, Inc. (NASDAQ:SYNH) By 39%?

Syneos Health, Inc. to Report Q4, 2021 Results on Feb 17, 2022